12:00 AM
 | 
Sep 20, 1999
 |  BC Week In Review  |  Company News  |  Deals

Cell Genesys, Hoechst Marion Roussel Inc. deal

CEGE reacquired from HMR worldwide rights to its gene therapy product that modifies autologous T cells to treat HIV infection/AIDS, which is in Phase II testing. CEGE will receive an $8 million payment from HMR...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >